Data science firm Genomics Plc names new Chief Strategy Officer

pharmafile | March 10, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing genomics, pharma 

Data science firm Genomics Plc, which lays claim to “the world’s largest genomic database”, has welcomed Mitchell Harris to the company and its senior leadership team as its Chief Strategy Officer.

Joining from his previous role as Global Head, Emerging Business Lines at Abcam, Harris’ career has given him ample experience in commercial strategy and operations. Prior to his most recent role at Abcam, he acted as the company’s Head of Proteins Portfolio Commercial and Business Development.

Before this, Harris had served a tenure at consultancy firm McKinsey & Company, where he “specialised in advising globally significant corporate and private equity clients on strategy, investment, and business model design; with a focus on life sciences and other high-tech industries”. At the company he formed part of its Pharmaceuticals and Medical Products Practice as Engagement Manager, and he also served as Principal at McKinsey’s AI and analytics arm Quantum Black.

During his time with McKinsey, Harris was also said to engage in public and social sector practice, “advising governments and social sector organisations on strategy, innovation, and economic growth”.

Earlier in his career, Harris also worked as a fast stream civil servant at the UK Cabinet Office, and as a Policy Fellow at the Centre for Science and Policy at the University of Cambridge between 2012 and 2015.

“I am thrilled to be joining Genomics plc and to work alongside world leaders in human genetics and data science,” Harris commented. “This is an exciting and pivotal time for the company’s growth as we accelerate and deepen our impact within drug development and genomic prevention. I hope that together with patients, healthcare systems, and our partners, we can play an important role in the quest for a new, more sustainable, and more equitable model of drug development and healthcare.”

Genomics CEO Sir Peter Donnelly welcomed Harris to the company, remarking: “Mitchell’s depth of knowledge and experience of the sector will enable him to support Genomics plc’s position at the forefront of this emerging field and help to deliver solutions to make healthcare and life sciences more efficient and effective.”

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and …

Latest content